Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 16/20 | 0.65 |
| ▸ | MMP9 | P14780 | 16/20 | 0.65 |
| ▸ | MMP3 | P08254 | 6/20 | 0.65 |
| ▸ | MMP1 | P03956 | 4/20 | 0.65 |
| ▸ | MMP8 | P22894 | 4/20 | 0.65 |
| ▸ | MMP13 | P45452 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6580404 | 0.89 | MMP2 (0.67) | MMP2MMP9MMP3MMP1MMP8 | |
| SCHEMBL7079056 | 0.87 | MMP2 (0.65) | MMP2MMP9MMP3MMP1MMP8 | |
| SCHEMBL7077896 | 0.85 | MMP2 (0.60) | MMP2MMP9MMP3MMP1MMP8 | |
| SCHEMBL7226591 | 0.81 | MMP2 (0.60) | MMP2MMP9MMP3MMP1MMP8 | |
| SCHEMBL9219366 | 0.79 | MMP2 (0.55) | MMP2MMP9MMP3MMP13ALDH1A1 | |
| SCHEMBL7074930 | 0.79 | MMP2 (1.00) | MMP2MMP9MMP3MMP1MMP8 | |
| SCHEMBL6575894 | 0.79 | CYP1A2 (0.49) | MMP2MMP9MMP3MMP13ALDH1A1 | |
| SCHEMBL7077886 | 0.78 | MMP2 (0.66) | MMP2MMP9MMP3MMP1MMP13 | |
| SCHEMBL7078207 | 0.78 | MMP2 (0.53) | MMP2MMP9MMP3MMP1MMP8 | |
| SCHEMBL7078652 | 0.74 | MMP1 (0.49) | MMP2MMP9MMP3MMP1MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0968182-B1 | HYDROXAMIC AND CARBOXYLIC ACID DERIVATIVES HAVING MMP AND TNF INHIBITORY ACTIVITY | DARWIN DISCOVERY LTD (GB) | 2004-05-06 | — | — | EP | disclosed |
| US-20030207889-A1 | Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity | OWEN DAVID ALAN (GB) | 2003-11-06 | — | — | US | disclosed |
| US-6566384-B1 | For therapy of cancer, inflammation and inflammatory diseases, tissue degeneration, periodontal disease, ophthalmological disease, dermatological disorders, fever, cardiovascular effects, haemorrhage, coagulation and acute phase response | DARWIN DISCOVERY LTD. (GB) | 2003-05-20 | — | — | US | disclosed |
| US-6118001-A | ANTICANCER AGENT; ANTIARTHRITIC AGENT | DARWIN DISCOVERY, LTD. (GB) | 2000-09-12 | — | — | US | disclosed |
| EP-0968182-A1 | HYDROXAMIC AND CARBOXYLIC ACID DERIVATIVES HAVING MMP AND TNF INHIBITORY ACTIVITY | Darwin Discovery Limited (GB) | 2000-01-05 | — | — | EP | disclosed |
| CN-1227540-A | Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity | DARWIN DISCOVERY CO LTD (GB) | 1999-09-01 | — | — | CN | disclosed |
| WO-1998005635-A1 | HYDROXAMIC AND CARBOXYLIC ACID DERIVATIVES HAVING MMP AND TNF INHIBITORY ACTIVITY | DARWIN DISCOVERY LIMITED (GB) | 1998-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207889-A1 | Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity | MMP13, MMP2, MMP9 | MMP2 2/4885MMP9 3/4885MMP3 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.